Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Sarah V. Holt"'
Autor:
Mark Austin, Daniel Burschowsky, Denice T.Y. Chan, Lesley Jenkinson, Stuart Haynes, Agata Diamandakis, Chitra Seewooruthun, Alexandra Addyman, Sebastian Fiedler, Stephanie Ryman, Jessica Whitehouse, Louise H. Slater, Andreas V. Hadjinicolaou, Uzi Gileadi, Ellen Gowans, Yoko Shibata, Michelle Barnard, Teresa Kaserer, Pooja Sharma, Nadia M. Luheshi, Robert W. Wilkinson, Tristan J. Vaughan, Sarah V. Holt, Vincenzo Cerundolo, Mark D. Carr, Maria A. T. Groves
Publikováno v:
mAbs, Vol 12, Iss 1 (2020)
Arginase 2 (ARG2) is a binuclear manganese metalloenzyme that catalyzes the hydrolysis of L-arginine. The dysregulated expression of ARG2 within specific tumor microenvironments generates an immunosuppressive niche that effectively renders the tumor
Externí odkaz:
https://doaj.org/article/e9b2ccb330b0476b8cb004d93c4045cc
Autor:
Paul D. Smith, Sylvie M. Guichard, Robert W. Wilkinson, Yi-Long Wu, Jingchuan Zhang, Yi Gu, Christine M. Chresta, Sarah Fenton, Sarah Runswick, Denis Alferez, Barry R. Davies, Armelle Logie, Sarah V. Holt
PDF file - 78K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b09df48d8cda4b53d0141eccb336a91
https://doi.org/10.1158/0008-5472.22392663.v1
https://doi.org/10.1158/0008-5472.22392663.v1
Autor:
Ellen Gowans, Stuart W. Haynes, Mark D. Carr, Stephanie Ryman, Maria A T Groves, Daniel Burschowsky, Tristan J Vaughan, Alexandra Addyman, Vincenzo Cerundolo, Agata Diamandakis, Chitra Seewooruthun, Yoko Shibata, Louise H. Slater, Sarah V. Holt, Denice T Y Chan, Sebastian Fiedler, Jessica Whitehouse, Robert W. Wilkinson, Lesley Jenkinson, Mark Austin, Michelle Barnard
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America
Significance We describe an antibody optimization strategy that seeks to overcome the restrictive nature of existing affinity-maturation methods, by rapidly exploring a vast sequence space in an unbiased manner through application of PCR techniques a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c87dfaaa68caca1deaad976192d14ea4
https://doi.org/10.1073/pnas.1919565117
https://doi.org/10.1073/pnas.1919565117
Autor:
Manish Patel, Kathleen N. Moore, Desiree Piscitello, Jayesh Majithiya, Marina Roy Luzarraga, Helen Millward, Sarah V. Holt, Melissa Johnson
Publikováno v:
Cancer Research. 82:LB520-LB520
Inhibition of ataxia telangiectasia and Rad-3 related (ATR) kinase offers therapeutic promise for DNA damage response deficient tumors. In addition, ATR inhibitors may offer even broader clinical utility when combined with PARPi’s, chemo, immune or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8339b39988ac45f52409a44d9375f61f
https://doi.org/10.1158/1538-7445.am2022-lb520
https://doi.org/10.1158/1538-7445.am2022-lb520
Autor:
Jessica Whitehouse, Mark D. Carr, Lesley Jenkinson, Daniel Burschowsky, Pooja Sharma, Teresa Kaserer, Mark Austin, Yoko Shibata, Michelle Barnard, Sebastian Fiedler, Alexandra Addyman, Denice T Y Chan, Uzi Gileadi, Tristan J Vaughan, Vincenzo Cerundolo, Stuart W. Haynes, Andreas V. Hadjinicolaou, Robert W. Wilkinson, Nadia Luheshi, Ellen Gowans, Stephanie Ryman, Chitra Seewooruthun, Louise H. Slater, Maria A T Groves, Sarah V. Holt, Agata Diamandakis
Publikováno v:
mAbs
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Arginase 2 (ARG2) is a binuclear manganese metalloenzyme that catalyzes the hydrolysis of L-arginine. The dysregulated expression of ARG2 within specific tumor microenvironments generates an immunosuppressive niche that effectively renders the tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d3b8cb1acf348ab6aadffa7fd707d02
http://europepmc.org/articles/PMC7531564
http://europepmc.org/articles/PMC7531564
Autor:
James W.T. Yates, Karen Woods, Robert W. Wilkinson, Sarah V. Holt, Kirsty Payne, Barry R. Davies, Armelle Logie, Sylvie Guichard
Publikováno v:
British Journal of Pharmacology. 174:2652-2661
Background AZD8055 is a potent orally available mTOR kinase inhibitor with in vitro and in vivo antitumour activity against a range of tumour types. Preclinical studies showed that AZD8055 induced a dose-dependent pharmacodynamic effect in xenograft
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c7c579c415311078d93d157fb8710067
https://doi.org/10.1111/bph.13886
https://doi.org/10.1111/bph.13886
Autor:
Denice Y Chan, Lesley Jenkinson, Mark Austin, Maria A T Groves, Lisa Ruff, Sarah V. Holt, Stuart W. Haynes, Richard J. Gilbertson
Publikováno v:
Neuro-Oncology
Ependymomas account for 10% of paediatric brain tumours and arise in the ventricular walls of the central nervous system. Ependymomas were previously classified as one tumour type and all patients received similar treatment. However, recent genomic s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92f8d6e07227e6a2e2347595bdda00ee
https://doi.org/10.1093/neuonc/noaa222.153
https://doi.org/10.1093/neuonc/noaa222.153
Autor:
James W T, Yates, Sarah V, Holt, Armelle, Logie, Kirsty, Payne, Karen, Woods, Robert W, Wilkinson, Barry R, Davies, Sylvie M, Guichard
Publikováno v:
British journal of pharmacology. 174(16)
AZD8055 is a potent orally available mTOR kinase inhibitor with in vitro and in vivo antitumour activity against a range of tumour types. Preclinical studies showed that AZD8055 induced a dose-dependent pharmacodynamic effect in xenograft models in v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d1fa9a6e9530284c20dc58908ceba490
https://pubmed.ncbi.nlm.nih.gov/28556895
https://pubmed.ncbi.nlm.nih.gov/28556895
Autor:
Sylvie Guichard, Robert W. Wilkinson, Sarah L. Fenton, Yi-Long Wu, Paul D. Smith, Jingchuan Zhang, Barry R. Davies, Armelle Logie, Sarah V. Holt, Sarah Runswick, D Alferez, Yi Gu, Christine M. Chresta
Publikováno v:
Cancer Research. 72:1804-1813
The mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase/AKT signaling pathways interact at multiple nodes in cancer, including at mTOR complexes, suggesting an increased likelihood of redundancy and innate resistance to any therapeu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72dae4cf385b4a4e49a80db38ebb80b8
https://doi.org/10.1158/0008-5472.can-11-1780
https://doi.org/10.1158/0008-5472.can-11-1780
Autor:
A Heier, Rajesh Odedra, Simon P. Heaton, Barry R. Davies, Armelle Logie, D Alferez, Robert W. Wilkinson, Paul D. Smith, Sarah V. Holt
Publikováno v:
British Journal of Cancer
Background: The Ras/RAF/MEK/ERK pathway is frequently deregulated in cancer and a number of inhibitors that target this pathway are currently in clinical development. It is likely that clinical testing of these agents will be in combination with stan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cd64d8860ac25e233325ad93fca0e4e
https://doi.org/10.1038/bjc.2012.8
https://doi.org/10.1038/bjc.2012.8